TENAX THERAPEUTICS, INC. (TENX)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 23, 2026

Verified against EDGAR
Total Assets
$121.7M
Stockholders' Equity
$113.6M
Cash & Equivalents
$118.0M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, TENAX THERAPEUTICS, INC. reported revenue of $0, net income of -$17.8M, and total assets of $121.7M. Every figure below is taken directly from TENAX THERAPEUTICS, INC.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$0-$52.6M
FY2024$0-$17.6M
FY2023—-$7.7M
FY2022—$11.0M
FY2021—-$32.5M
FY2020—-$9.9M
FY2019—-$8.4M
FY2018—-$14.1M
FY2017—-$8.8M
FY2016$0-$43.9M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 8, 2026on EDGAR ↗
8-KSep 9, 2026on EDGAR ↗
8-KAug 10, 2026on EDGAR ↗
8-KJul 31, 2026on EDGAR ↗
10-QJul 31, 2026on EDGAR ↗
8-KJul 2, 2026on EDGAR ↗
8-KJun 30, 2026on EDGAR ↗
8-KJun 29, 2026on EDGAR ↗
8-KJun 4, 2026on EDGAR ↗
10-QMay 12, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$121.7Msource ↗
Stockholders’ Equity$113.6Msource ↗
Cash & Equivalents$118.0Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue$0source ↗
Net Income-$17.8Msource ↗
Operating Income-$18.8Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$12.8Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.35source ↗
EPS (basic)$-0.35source ↗
Shares Outstanding37.4Msource ↗
Cash from Operations-$14.2Msource ↗
Cash from Financing$13.4Msource ↗
Cash from Investing—source ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
14
Sells
0
Net shares
+3.7M

Restatement history

Point-in-time

10 of 372 annual fact-keys were materially restated between filings: what TENAX THERAPEUTICS, INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches TENX’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/TENX

MCP tool: get_sec_fundamentals ticker=TENX

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/TENX/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=TENX as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/TENX/history

MCP tool: get_fundamentals_history ticker=TENX

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/TENX

MCP tool: get_financial_health ticker=TENX

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.